Autolus Therapeutics taps investors for $100m
Autolus Therapeutics, the UK biopharmaceutical company focused on T cell therapies for cancer, is raising additional capital on the Nasdaq.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: